SCHEMBL12974209

SCHEMBL12974209

O=C(Nc1ncc([N+](=O)[O-])s1)c1cc(Cl)ccc1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 9/20 0.75
MEN1 O00255 8/20 0.59
RAB9A P51151 8/20 0.59
KMT2A Q03164 8/20 0.59
NPC1 O15118 7/20 0.59
POLB P06746 1/20 0.59
MAPT P10636 5/20 0.58
LMNA P02545 4/20 0.58
HTT P42858 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
ALDH1A1 P00352 3/20 0.58
KCNMA1 Q12791 1/20 0.56
P2RX1 P51575 1/20 0.56
ATG4B Q9Y4P1 2/20 0.56
NPY1R P25929 2/20 0.56
PKM P14618 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
THRB P10828 1/20 0.55
MAPK9 P45984 1/20 0.55
TP53 P04637 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30771758 1.00 STAT3 (0.75) STAT3MEN1RAB9AKMT2ANPC1
SCHEMBL29908285 0.86 STAT3 (1.00) STAT3MEN1RAB9AKMT2ANPC1
SCHEMBL5797958 0.86 STAT3 (1.00) STAT3MEN1RAB9AKMT2ANPC1
SCHEMBL12974224 0.86 STAT3 (0.75) STAT3MEN1RAB9AKMT2ANPC1
SCHEMBL25063337 0.85 STAT3 (0.70) STAT3MEN1RAB9AKMT2ANPC1
Tizoxanide SCHEMBL375440 0.83 STAT3 (1.00) STAT3MEN1RAB9AKMT2ANPC1
Tizoxanide SCHEMBL29367981 0.83 STAT3 (1.00) STAT3MEN1RAB9AKMT2ANPC1
SCHEMBL23674262 0.82 STAT3 (0.60) STAT3MEN1RAB9AKMT2ANPC1
SCHEMBL12974203 0.82 STAT3 (0.74) STAT3MEN1RAB9AKMT2ANPC1
SCHEMBL30472740 0.82 KCNMA1 (0.64) STAT3MEN1KMT2AKCNMA1P2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002332-A1 Small Molecule Inhibitors of SARS-CoV-2 Infections THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION 2024-01-04 US claimed
US-20190070154-A1 NEW METHODS OF USE FOR AN ANTI-DIARRHEA AGENT DUKE UNIVERSITY 2019-03-07 US claimed
WO-2016210247-A1 NEW METHODS OF USE FOR AN ANTI-DIARRHEA AGENT DUKE UNIVERSITY (US) 2016-12-29 WO claimed
US-20240002332-A1 Small Molecule Inhibitors of SARS-CoV-2 Infections THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION 2024-01-04 US disclosed
US-11850237-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2023-12-26 US disclosed
US-11850237-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2023-12-26 US disclosed
EP-3895706-A1 THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS Romark Laboratories, L.C. (US) 2021-10-20 EP disclosed
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2021-06-17 US disclosed
US-10912768-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2021-02-09 US disclosed
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2019-10-10 US disclosed
US-10363243-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2019-07-30 US disclosed
US-9345690-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2016-05-24 US disclosed
US-9345690-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2016-05-24 US disclosed
US-20150250768-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2015-09-10 US disclosed
US-20150250768-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2015-09-10 US disclosed
US-9023877-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2015-05-05 US disclosed
US-9023877-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2015-05-05 US disclosed
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. 2010-12-30 US disclosed
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. 2010-12-30 US disclosed
WO-2010151577-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002332-A1 Small Molecule Inhibitors of SARS-CoV-2 Infections ACE2, ACE, TMPRSS2 STAT3 1507/4885MEN1 4741/4885RAB9A 867/4885
US-20150250768-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885RAB9A 1890/4885
US-10912768-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885RAB9A 1890/4885
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885RAB9A 1890/4885
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885RAB9A 1890/4885
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885RAB9A 1890/4885
US-11850237-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885RAB9A 1890/4885
US-10363243-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885RAB9A 1890/4885
US-20190070154-A1 NEW METHODS OF USE FOR AN ANTI-DIARRHEA AGENT FZD7, SFRP1, WNT1 STAT3 146/4885MEN1 3553/4885RAB9A 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.